The company, which focuses on occupational wellness platforms for procedural medicine, intends to use the capital to scale production and support its revenue growth. Salus Scientific designs protective solutions for medical professionals performing fluoroscopy-guided procedures, a niche that has attracted increased attention from clinical investors.

Todd Flohr, Chairman and CEO of Salus Scientific, characterized the oversubscribed round as a validation of the company's execution and market strategy. By closing the Series A early, management aims to solidify its position in the healthcare sector while expanding the reach of its safety-focused technology for physicians and technologists.